Saphris (SA-fris), a new atypical antipsychotic for schizophrenia and bipolar disorder

October 2009

Reps will promote Saphris (SA-fris), a new atypical antipsychotic for schizophrenia and bipolar disorder.

They will point out that Saphris (asenapine) seems well tolerated.

Saphris does seem to cause less weight gain and other metabolic problems than risperidone or Zyprexa (olanzapine).

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote